



Wellmark Blue Cross and Blue Shield is an Independent Licensee of the Blue Cross and Blue Shield Association.

DRUG POLICY

Enzyme Replacement Therapy

NOTICE

This policy contains information which is clinical in nature. The policy is not medical advice. The information in this policy is used by Wellmark to make determinations whether medical treatment is covered under the terms of a Wellmark member's health benefit plan. Physicians and other health care providers are responsible for medical advice and treatment. If you have specific health care needs, you should consult an appropriate health care professional. If you would like to request an accessible version of this document, please contact customer service at 800-524-9242.

BENEFIT APPLICATION

Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations or exceptions may apply. Benefits may vary based on contract, and individual member benefits must be verified. Wellmark determines medical necessity only if the benefit exists and no contract exclusions are applicable. This policy may not apply to FEP. Benefits are determined by the Federal Employee Program.

DESCRIPTION

The intent of the Enzyme Replacement Therapy policy is to ensure appropriate selection of patients for therapy based on product labeling, clinical guidelines and clinical studies while steering utilization to the most cost-effective medication within the therapeutic class.

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met, and the member has no exclusions to the prescribed therapy. All other indications are considered experimental/investigational and not medically necessary.

FDA-Approved Indications

- I. **Adzynma (ADAMTS13, recombinant-krhn)** is indicated for prophylactic or on demand enzyme replacement therapy (ERT) in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP).
- II. **Aldurazyme (aronidase)** is indicated for adult and pediatric patients with Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I) and for patients with the Scheie form who have moderate to severe symptoms. The risks and benefits of treating mildly affected patients with the Scheie form have not been established. The effect of Aldurazyme on central nervous system manifestations of the disorder has not been determined.
- III. **Brineura (cerliponase alfa)** is indicated to slow the loss of ambulation in pediatric patients with neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase 1 (TPP1) deficiency.
- IV. **Elaprased (idursulfase)** is indicated for patients with Hunter syndrome (Mucopolysaccharidosis II, MPS II). Elaprased has been shown to improve walking capacity in patients 5 years and older. In patients 16 months to 5 years of age, no data are available to demonstrate improvement in disease-related symptoms or long-term clinical outcome; however, treatment with Elaprased has reduced

- spleen volume similarly to that of adults and children 5 years of age and older. The safety and efficacy of Elaprase have not been established in pediatric patients less than 16 months of age.
- V. **Elfabrio (pegunigalsidase alfa-iwxj)** is indicated for the treatment of adults with confirmed Fabry disease.
 - VI. **Fabrazyme (agalsidase beta)** is indicated for the treatment of adult and pediatric patients 2 years of age and older with confirmed Fabry disease.
 - VII. **Kanuma (sebelipase alfa)** is indicated for the treatment of patients with a diagnosis of Lysosomal Acid Lipase (LAL) deficiency.
 - VIII. **Lamzede (velmanase alfa-tycv)** is indicated for the treatment of non-central nervous system manifestations of alpha-mannosidosis in adult and pediatric patients.
 - IX. **Lumizyme (alglucosidase alfa)** is indicated for patients with Pompe disease (acid alpha-glucosidase [GAA] deficiency).
 - X. **Nexviazyme (avalglucosidase alfa-ngpt)** is indicated for the treatment of patients 1 year of age and older with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency).
 - XI. **Mepsevii (vestronidase alfa-vjbjk)** is indicated in pediatric and adult patients for the treatment of mucopolysaccharidosis VII (MPS VII, Sly syndrome).
 - XII. **Naglazyme (galsulfase)** is indicated for patients with mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome). Naglazyme has been shown to improve walking and stair-climbing capacity.
 - XIII. **Nulibry (fodenoferin)** is cyclic pyranopterin monophosphate (cPMP) indicated to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A.
 - XIV. **Opfolda (miglustat)** is indicated, in combination with Pombiliti, for the treatment of adult patients with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency) weighing greater than or equal to 40 kg and who are not improving on their current enzyme replacement therapy (ERT).
 - XV. **Pombiliti (cipaglucosidase alfa-atga)** is indicated, in combination with Opfolda, for the treatment of adult patients with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency) weighing greater than or equal to 40 kg and who are not improving on their current enzyme replacement therapy (ERT).
 - XVI. **Revcovi (elapegedemase-ivlr)** is indicated for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients.
 - XVII. **Vimizim (elosulfase alfa)** is indicated for patients with Mucopolysaccharidosis type IVA (MPS IVA, Morquio A syndrome).
 - XVIII. **Xenpozyme (olipudase alfa-rpcp)** is indicated for the treatment of non-central nervous system manifestations of acid sphingomyelinase deficiency (ASMD) in adult and pediatric patients.

POLICY

Required Documentation

Submission of the following information is necessary to initiate the prior authorization review:

- I. **Adzyna (ADAMTS13, recombinant-krhn)**
 - a. Initial requests: ADAMTS13 enzyme assay and ADAMTS13 genetic testing results supporting the diagnosis.
 - b. Continuation of therapy requests: Medical records (e.g., chart notes, lab reports) documenting a response to therapy (e.g., reduction or maintenance of number of thrombotic thrombocytopenic purpura [TTP] events, increase in platelet count, decrease in lactate dehydrogenase [LDH] level).
- II. **Aldurazyme (aronidase)**
 - a. Initial requests: alpha-L-iduronidase enzyme assay and/or genetic testing results supporting diagnosis.
 - b. Continuation requests: chart notes documenting a clinically positive response to therapy, which shall include improvement, stabilization, or slowing of disease progression.
- III. **Brineura (cerliponase alfa)**

- a. Initial requests: Tripeptidyl peptidase 1 (TPP1) enzyme assay or genetic testing results supporting diagnosis
 - b. Continuation requests: chart notes documenting a clinically positive response to therapy, which shall include improvement, stabilization, or slowing of disease progression.
- IV. Elaprase (idursulfase)**
- a. Initial requests: iduronate 2-sulfatase enzyme assay or genetic testing results supporting diagnosis.
 - b. Continuation requests: chart notes documenting a clinically positive response to therapy, which shall include improvement, stabilization, or slowing of disease progression.
- V. Elfabrio (pegunigalsidase alfa-iwxj)**
- a. Initial requests: alpha-galactosidase enzyme assay or genetic testing results supporting diagnosis. In the case of obligate carriers, the documentation must be submitted for the parent.
 - b. Continuation requests: lab results or chart notes documenting a positive response to therapy (e.g., reduction in plasma globotriaosylceramide [GL-3, Gb3] or GL-3/Gb3 inclusions, improvement and/or stabilization in renal function, pain reduction).
- VI. Fabrazyme (agalsidase beta)**
- a. Initial requests: alpha-galactosidase enzyme assay or genetic testing results supporting diagnosis. In the case of obligate carriers, the documentation must be submitted for the parent.
 - b. Continuation requests: lab results or chart notes documenting a positive response to therapy (e.g., reduction in plasma globotriaosylceramide [GL-3, Gb3] or GL-3/Gb3 inclusions, improvement and/or stabilization in renal function, pain reduction).
- VII. Kanuma (sebelipase alfa)**
- a. Initial requests: lysosomal acid lipase enzyme assay or genetic testing results supporting diagnosis
 - b. Continuation requests: lab values or chart notes documenting a positive response to therapy (e.g., improvement, stabilization, or slowing of disease progression for weight-for-age z-score if exhibiting growth failure, LDL, HDL, triglycerides, or ALT).
- VIII. Lamzede (velmanase alfa-tycv)**
- a. Initial requests:
 - i. Alpha-mannosidase enzyme assay or genetic testing results supporting the diagnosis.
 - ii. Chart notes or medical records documenting absence of neurological manifestations of alpha-mannosidosis.
 - b. Continuation requests: documentation (e.g., chart notes, lab results) of a response to therapy (e.g., improvement in 3-minute stair climbing test [3MSCT] from baseline, improvement in 6-minute walking test [6MWT] from baseline, improvement in forced vital capacity [FVC, % predicted] from baseline, reduction in serum or urine oligosaccharide concentration from baseline).
- IX. Lumizyme (alglucosidase alfa)**
- a. Initial requests: acid alpha-glucosidase enzyme assay or genetic testing results supporting diagnosis
 - b. Continuation requests: chart notes documenting a positive response to therapy (e.g., improvement, stabilization, or slowing of disease progression for motor function, walking capacity, cardiorespiratory function, decrease in left ventricular mass index [LVMI], delay in death).
- X. Nexviazyme (alglucosidase alfa-ngpt)**
- a. Initial requests: acid alpha-glucosidase enzyme assay or genetic testing results supporting diagnosis
 - b. Continuation requests: chart notes documenting a positive response to therapy (e.g., improvement, stabilization, or slowing of disease progression for motor function, walking capacity, respiratory function, muscle strength).
- XI. Nulibry (fosdenopterin)**
- a. Initial requests: genetic testing results documenting a mutation in the molybdenum cofactor synthesis gene 1 (*MOSC1*).

- b. Continuation requests:
 - i. Genetic testing results documenting a mutation in the molybdenum cofactor synthesis gene 1 (*MOSC1*).
 - ii. Chart notes or medical records documenting a benefit from therapy (e.g., improvement, stabilization, or slowing of disease progression for encephalopathy, seizure activity, improved or normalized uric acid, urinary S-sulfocysteine, and xanthine levels).
- XII. Mepsevii (vestronidase alfa-vjvk)**
 - a. Initial requests: beta-glucuronidase enzyme assay or genetic testing results supporting diagnosis
 - b. Continuation requests: chart notes documenting a clinically positive response to therapy, which shall include improvement, stabilization, or slowing of disease progression.
- XIII. Naglazyme (galsulfase)**
 - a. Initial requests: N-acetylgalactosamine 4-sulfatase (arylsulfatase B) enzyme assay or genetic testing results supporting diagnosis
 - b. Continuation requests: chart notes documenting a clinically positive response to therapy, which shall include improvement, stabilization, or slowing of disease progression.
- XIV. Opfolda (miglustat)**
 - a. Initial requests: acid alpha-glucosidase enzyme assay or genetic testing results supporting diagnosis.
 - b. Continuation requests: chart notes documenting a positive response to therapy (e.g., improvement, stabilization, or slowing of disease progression for motor function, walking capacity, respiratory function, muscle strength).
- XV. Pombiliti (cipaglucoisidase alfa-atga)**
 - a. Initial requests: acid alpha-glucosidase enzyme assay or genetic testing results supporting diagnosis.
 - b. Continuation requests: chart notes documenting a positive response to therapy (e.g., improvement, stabilization, or slowing of disease progression for motor function, walking capacity, respiratory function, muscle strength).
- XVI. Revcovi (elapegademase-lvlr)**
 - a. Initial requests: Enzyme assay or genetic testing results supporting diagnosis of ADA deficiency
 - b. Continuation requests: chart notes documenting a clinically positive response to therapy as evidenced by disease stability or disease improvement (e.g., normalization of plasma ADA activity, erythrocyte dATP levels, improvement of disease symptoms, etc.).
- XVII. Vimizim (elosulfase alfa)**
 - a. Initial requests: N-acetylgalactosamine 6-sulfatase enzyme assay or genetic testing results supporting diagnosis
 - b. Continuation requests: chart notes documenting a clinically positive response to therapy, which shall include improvement, stabilization, or slowing of disease progression.
- XVIII. Xenpozyme (olipudase alfa-rpcp)**
 - a. Initial requests: acid sphingomyelinase enzyme assay or genetic testing results supporting the diagnosis
 - b. Continuation requests: documentation (e.g., chart notes, lab results) of a response to therapy (e.g., improvement in lung function, reduction in spleen volume, reduction in liver volume, improvement in platelet count, improvement in linear growth progression)

Prescriber Specialties

- I. **Aldurazyme (laronidase), Elfabrio (pegunigalsidase alfa-iwxj), Elapraxe (idursulfase), Fabrazyme (agalsidase beta), Kanuma (sebelipase alfa), Lumizyme (alglucosidase alfa), Mepsevii (vestronidase alfa-vibk), Naglazyme (galsulfase), Nexviazyme (alglucosidase alfa-ngpt), Nulibry (fosdenopterin), Opfolda (miglustat), Pombiliti (cipaglucoisidase alfa-atga), Vimizim (elosulfase alfa) only**

- a. These medications must be prescribed by or in consultation with a physician who specializes in the treatment of metabolic disease and/or lysosomal storage disorders.

Criteria for Initial Approval

- I. **Adzyna (ADAMTS13, recombinant-krhn)** is considered **medically necessary** for treatment of congenital thrombotic thrombocytopenic purpura (cTTP) when ALL the following criteria are met:
 - a. The diagnosis of cTTP has been confirmed by genetic testing with biallelic mutations in the ADAMTS13 gene.
 - b. Member has an ADAMTS13 activity level of less than 10% at the time of diagnosis.

Approval is for 6 months

- II. **Aldurazyme (aronidase)** is considered **medically necessary** for treatment of Mucopolysaccharidosis I (MPS I) when ALL the following criteria are met:
 - a. Diagnosis of MPS I was confirmed by enzyme assay demonstrating a deficiency of alpha-L-iduronidase enzyme activity and/or by genetic testing.
 - b. Member has one of the following:
 - i. The Hurler form (i.e. severe MPS I).
 - ii. The Hurler-Scheie form (i.e. attenuated MPS I).
 - iii. The Scheie form (Scheie syndrome/i.e. attenuated MPS I) with moderate to severe symptoms (e.g., normal intelligence, less progressive physical problems, corneal clouding, joint stiffness, valvular heart disease).

Approval is for 12 months

- III. **Brineura (cerliponase alfa)** is considered **medically necessary** for members with neuronal ceroid lipofuscinosis type 2 (CLN2) when ALL the following criteria are met:
 - a. Diagnosis of CLN2 was confirmed by enzyme assay demonstrating a deficiency of tripeptidyl peptidase 1 (TPP1) enzyme activity or by genetic testing
 - b. Brineura will be administered by, or under the direction of a physician knowledgeable in intraventricular administration
 - c. Dosage of Brineura will not exceed 300 mg once every other week
 - d. Member does not have acute intraventricular access device-related complications (e.g., leakage, device failure, or device-related infection) or a ventriculoperitoneal shunt.
 - e. Documentation of baseline motor function using the motor domain of CLN2 Clinical Rating Scale confirms the member is ambulatory at the time of treatment initiation.

Approval is for 12 months

- IV. **Elaprase (idursulfase)** is considered **medically necessary** for treatment of Mucopolysaccharidosis II (MPS II) when the diagnosis of MPS II was confirmed by enzyme assay demonstrating a deficiency of iduronate 2-sulfatase enzyme activity or by genetic testing.

Approval is for 12 months

- V. **Elfabrio (pegunigalsidase alfa-iwxj)** is considered **medically necessary** for treatment of Fabry disease when ALL the following criteria are met:
 - a. Member is 18 years of age or older
 - b. The diagnosis of Fabry disease was confirmed by enzyme assay demonstrating a deficiency of alpha-galactosidase enzyme activity or by genetic testing, or the member is a symptomatic obligate carrier; and

- c. Elfabrio will not be used in combination with Galafold.

Approval is for 12 months

- VI. Fabrazyme (agalsidase beta)** is considered **medically necessary** for treatment of Fabry disease when ALL the following criteria are met:
- a. Member is 2 years of age or older
 - b. The diagnosis of Fabry disease was confirmed by enzyme assay demonstrating a deficiency of alpha-galactosidase enzyme activity or by genetic testing, or the member is a symptomatic obligate carrier.
 - c. Fabrazyme will not be used in combination with Galafold.

Approval is for 12 months

- VII. Kanuma (sebelipase alfa)** is considered **medically necessary** for treatment of Lysosomal Acid Lipase (LAL) deficiency when ALL the following criteria are met:
- a. Diagnosis of LAL deficiency was confirmed by enzyme assay demonstrating a deficiency of lysosomal acid lipase enzyme activity or by genetic testing.
 - b. Member has alanine aminotransferase level (ALT) ≥ 1.5 times the upper limit of normal (based on the age- and gender-specific normal ranges) on two consecutive ALT measurements obtained at least one week apart.

Approval is for 12 months

- VIII. Lamzede (velmanase alfa-tycv)** is considered **medically necessary** for treatment of non-central nervous system manifestations of alpha-mannosidosis when the following criteria is met:
- a. Diagnosis is confirmed by one of the following:
 - i. A documented deficiency of alpha-mannosidase activity as measured in blood leukocytes or fibroblasts, or
 - ii. Genetic testing results documenting a mutation in the *MAN2B1* gene.
 - b. The requested medication must be prescribed by, or in consultation with, a geneticist, hepatologist, gastroenterologist, pulmonologist, or other specialist with expertise in the diagnosis and management of non-CNS disease manifestations of alpha-mannosidosis.
 - c. Member is not being treated for CNS disease manifestations of alpha-mannosidosis.
 - d. Member does not have a history of hematopoietic stem cell transplantation or bone marrow transplant.
 - e. Dose does not exceed 1mg/kg once weekly

Approval is for 12 months

- IX. Lumizyme (alglucosidase alfa)** is considered **medically necessary** for treatment of Pompe disease when the diagnosis of Pompe disease was confirmed by enzyme assay demonstrating a deficiency of acid alpha-glucosidase enzyme activity or by genetic testing.

Approval is for 12 months

- X. Nexviazyme (alglucosidase alfa-ngpt)** is considered **medically necessary** for treatment of late-onset Pompe disease when the following criteria is met:
- a. Diagnosis of Pompe disease was confirmed by enzyme assay demonstrating a deficiency of acid alpha-glucosidase enzyme activity or by genetic testing.
 - b. Member is 1 year of age or older

Approval is for 12 months

- XI. Nulibry (fosdenopterin)** is considered **medically necessary** for treatment of molybdenum cofactor deficiency (MoCD) Type A when all of the following criteria are met:
- Member has clinical signs and symptoms associated with MoCD Type A (e.g., encephalopathy, intractable seizures, developmental delay, decreased uric acid levels, elevated urinary S-sulfocysteine and/or xanthine levels).
 - Member has a presumed diagnosis of MoCD Type A and genetic test results are pending.

Approval is for 3 months

OR

- Diagnosis of MoCD Type A was confirmed by genetic testing documenting a mutation in the molybdenum cofactor synthesis 1 (*MOSC1*) gene.

Approval is for 12 months

- XII. Mepsevii (vestronidase alfa-vjbn)** is considered **medically necessary** for treatment of mucopolysaccharidosis VII (MPS VII, Sly Syndrome) when ALL the following criteria are met:
- Diagnosis of MPS VII was confirmed by enzyme assay demonstrating a deficiency of beta-glucuronidase enzyme activity or by genetic testing.
 - Elevated urinary glycosaminoglycan (uGAG) excretion at a minimum of 2-fold over the mean normal for age at initiation of treatment with Mepsevii.

Approval is for 12 months

- XIII. Naglazyme (galsulfase)** is considered **medically necessary** for treatment of mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome) when the diagnosis of MPS VI was confirmed by enzyme assay demonstrating a deficiency of N-acetylgalactosamine 4-sulfatase (arylsulfatase B) enzyme activity or by genetic testing.

Approval is for 12 months

- XIV. Opfolda (miglustat)** is considered **medically necessary** for treatment of late-onset Pompe disease when all of the following criteria are met:
- Member is 18 years of age or older.
 - Member weighs greater than or equal to 40 kg.
 - Diagnosis was confirmed by enzyme assay demonstrating a deficiency of acid alpha-glucosidase enzyme activity or by genetic testing.
 - The requested medication will be taken in combination with Pombiliti (cipaglucosidase alfa-atga).
 - Member is not improving on current enzyme replacement therapy (ERT) (e.g., Lumizyme, Nexviazyme).

Approval is for 12 months

- XV. Pombiliti (cipaglucosidase alfa-atga)** is considered **medically necessary** for treatment of late-onset Pompe disease when all of the following criteria are met:
- Member is 18 years of age or older.
 - Member weighs greater than or equal to 40 kg.
 - Diagnosis was confirmed by enzyme assay demonstrating a deficiency of acid alpha-glucosidase enzyme activity or by genetic testing.
 - The requested medication will be taken in combination with Opfolda (miglustat).

- e. Member is not improving on current enzyme replacement therapy (ERT) (e.g., Lumizyme, Nexviazyme).

Approval is for 12 months

- XVI. Revcovi (elapegedemase-ivlr)** is considered **medically necessary** for treatment of severe combined immunodeficiency disease (SCID) associated with adenosine deaminase (ADA) deficiency when ALL the following criteria are met:
- a. The condition has failed to respond to a bone marrow transplant (BMT), or the member is not currently a suitable candidate for BMT.

Approval is for 12 months

- XVII. Vimizim (elosulfase alfa)** is considered **medically necessary** for treatment of Mucopolysaccharidosis type IVA (MPS IVA, Morquio A syndrome) when the diagnosis of MPS IVA was confirmed by enzyme assay demonstrating a deficiency of N-acetylgalactosamine 6-sulfatase enzyme activity or by genetic testing.

Approval is for 12 months

- XVIII. Xenpozyme (olipudase alfa-rpcp)** is considered **medically necessary** for the treatment of non-central nervous system manifestations of acid sphingomyelinase deficiency (ASMD) in adult and pediatric patients when the following criteria are met:
- a. Diagnosis is confirmed by one of the following:
 - i. A documented deficiency of acid sphingomyelinase (ASM) as measured in peripheral leukocytes, cultured fibroblasts, or lymphocytes; **OR**
 - ii. Genetic testing results documenting a mutation in the sphingomyelin phosphodiesterase-1 (SMPD1) gene.
 - b. The requested medication must be prescribed by or in consultation with a physician knowledgeable in the management of acid sphingomyelinase deficiency (ASMD).

Approval is for 12 months

Continuation of Therapy

- I. **Adzynma (ADAMTS13, recombinant-krhn)** is considered **medically necessary** for continuation of treatment of congenital thrombotic thrombocytopenic purpura (cTTP) in members who are responding to therapy (e.g., reduction or maintenance of number of thrombotic thrombocytopenic purpura [TTP] events, increase in platelet count, decrease in lactate dehydrogenase [LDH] level).

Approval is for 12 months

- II. **Aldurazyme (laronidase)** is considered **medically necessary** for continuation of treatment of Mucopolysaccharidosis I (MPS I) in members who have a clinically positive response to therapy (e.g., improvement, stabilization, or slowing of disease progression).

Approval is for 12 months

- III. **Brineura (cerliponase alfa)** is considered **medically necessary** for continuation of treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) when ALL the following criteria are met:
 - a. Member has experienced no loss or a slowed loss of ambulation from baseline; and

- b. Member does not have acute intraventricular access device-related complications (e.g., leakage, device failure, or device-related infection) or ventriculoperitoneal shunts.

Approval is for 12 months

- IV. **Elaprase (idursulfase)** is considered **medically necessary** for continuation of treatment for mucopolysaccharidosis II (MPS II) who have a clinically positive response to therapy, which shall include improvement, stabilization, or slowing of disease progression.

Approval is for 12 months

- V. **Elfabrio (pegunigalsidase alfa-iwxj)** is considered **medically necessary** for continuation of treatment of Fabry disease in members who are responding to therapy (e.g., reduction in plasma globotriasylceramide [GL-3, Gb3] or GL-3/Gb3 inclusions, improvement and/or stabilization in renal function, pain reduction).

Approval is for 12 months

- VI. **Fabrazyme (agalsidase beta)** is considered **medically necessary** for continuation of treatment of Fabry disease in members who are responding to therapy (e.g., reduction in plasma globotriaosylceramide [GL-3, Gb3] or GL-3/Gb3 inclusions, improvement and/or stabilization in renal function, pain reduction).

Approval is for 12 months

- VII. **Kanuma (sebelipase alfa)** is considered **medically necessary** for continuation of treatment of lysosomal acid lipase (LAL) deficiency in members who are responding to therapy (e.g., improvement, stabilization, or slowing of disease progression for weight-for-age z-score if exhibiting growth failure, low-density lipoprotein [LDL], high-density lipoprotein [HDL], triglycerides, or alanine aminotransferase [ALT]).

Approval is for 12 months

- VIII. **Lamzede (velmanase alfa-tycv)** is considered **medically necessary** for continuation of treatment of non-CNS manifestations of alpha-mannosidosis in members when the member meets all Criteria for Initial Approval above and is experiencing a positive clinical response to therapy (e.g., improvement in 3-minute stair climbing test [3MSCT] from baseline, improvement in 6-minute walking test [6MWT] from baseline, improvement in forced vital capacity [FVC, % predicted] from baseline, reduction in serum or urine oligosaccharide concentration from baseline).

Approval is for 12 months

- IX. **Lumizyme (alglucosidase alfa)** is considered **medically necessary** for continuation of treatment of Pompe disease in members who are responding to therapy (e.g., improvement, stabilization, or slowing of disease progression for motor function, walking capacity, cardiorespiratory function, decrease in left ventricular mass index (LVMI), delay in death).

Approval is for 12 months

- X. **Nexviazyme (alglucosidase alfa-ngpt)** is considered **medically necessary** for continuation of treatment of late-onset Pompe disease in members who are responding to therapy (e.g.,

improvement, stabilization, or slowing of disease progression for motor function, walking capacity, respiratory function, or muscle strength).

Approval is for 12 months

- XI. **Nulibry (fosdenopterin)** is considered **medically necessary** for continuation of treatment of MoCD Type A when one of the following is met:
- a. The member has received less than 12 months of therapy and has genetic testing results documenting pathogenic variant (s) in the molybdenum cofactor synthesis 1 (*MOSC1*) gene.
 - b. Member has received 12 months of therapy or more and is experiencing benefit from therapy (e.g., improvement, stabilization, or slowing of disease progression for encephalopathy, seizure activity, improved or normalized uric acid, urinary S-sulfocysteine, and xanthine levels).

Approval is for 12 months

- XII. **Mepsevii (vestronidase alfa-vjvk)** is considered **medically necessary** for continuation of treatment of mucopolysaccharidosis VII (MPS VII, Sly syndrome) in members who have a clinically positive response to therapy, which shall include improvement, stabilization, or slowing of disease progression.

Approval is for 12 months

- XIII. **Naglazyme (galsulfase)** is considered **medically necessary** for continuation of treatment of mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome) in members who have a clinically positive response to therapy, which shall include improvement, stabilization, or slowing of disease progression.

Approval is for 12 months

- XIV. **Opfolda (miglustat)** is considered **medically necessary** for continuation of treatment of late-onset Pompe disease in members who are responding to therapy (e.g., improvement, stabilization, or slowing of disease progression for motor function, walking capacity, respiratory function, or muscle strength).

Approval is for 12 months

- XV. **Pombiliti (cipaglucosidase alfa-atga)** is considered **medically necessary** for continuation of treatment of late-onset Pompe disease when both of the following criteria are met:
- a. Member is responding to therapy (e.g., improvement, stabilization, or slowing of disease progression for motor function, walking capacity, respiratory function, or muscle strength).
 - b. The requested medication will be taken in combination with Opfolda (miglustat).

Approval is for 12 months

- XVI. **Revcovi (elapegedemase-lvir)** is considered **medically necessary** for continuation of treatment of severe combined immunodeficiency disease (SCID) associated with adenosine deaminase (ADA) deficiency in members who are responding to therapy as evidenced by disease stability or disease improvement (e.g., normalization of plasma ADA activity, erythrocyte dATP levels, improvement of disease symptoms, etc.).

Approval is for 12 months

XVII. **Vimizim (elosulfase alfa)** is considered **medically necessary** for continuation of treatment of mucopolysaccharidosis type IVA (MPS IVA, Morquio A syndrome) in members who have a clinically positive response to therapy, which shall include improvement, stabilization, or slowing of disease progression.

Approval is for 12 months

XVIII. **Xenpozyme (olipudase alfa-rpcp)** is considered **medically necessary** for continuation of treatment of acid sphingomyelinase deficiency (ASMD) in members who are responding to therapy (e.g., improvement in lung function, reduction in spleen volume, reduction in liver volume, improvement in platelet count, improvement in linear growth progression).

Approval is for 12 months

The enzyme replacement therapies in this policy are considered **not medically necessary** for members who do not meet the criteria set forth above.

Dosing and Administration

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

CLINICAL RATIONALE

Background

Lysosomal storage diseases are inherited metabolic diseases that are characterized by an abnormal build-up of various toxic materials in the body's cells as a result of enzyme deficiencies. There are nearly 50 of these disorders altogether, and they may affect different parts of the body, including the skeleton, brain, skin, heart, and central nervous system. There is no cure for lysosomal storage disorders, and there are not yet specific treatments for many of these diseases. However, progress is being made in the search for therapies, and there are treatments available such as enzyme replacement therapy (ERT) which have been proven effective for some lysosomal storage disorders that greatly improve the quality of life for those affected.

Although the signs and symptoms vary from disease to disease in this group, symptoms occur in each case because of an enzyme deficiency that inhibits the ability of the lysosomes present in each of the body's cells to perform their normal function. The lysosomes function as the primary digestive units within cells. Their function is to break down complex components into simpler ones. Each cell has hundreds of lysosomes that degrade complex cellular components such as proteins (substrates) into simpler components. When this process does not take place, the substrate begins to accumulate in the cells. That is why these diseases are called "storage diseases". The symptoms of lysosomal storage disorders are generally progressive over a period of time.

Fabry Disease

On April 24, 2003, FDA approved Fabrazyme (Agalsidase beta), a recombinant human -galactosidase A (Gal A) enzyme for use in patients with Fabry disease, and on May 9, 2023, Elfabrio (Pegunigalsidase alfa-iwxj) was the second enzyme replacement therapy to be approved by the FDA for the treatment of adults with confirmed Fabry disease. Fabry disease is a rare X-linked recessive lysosomal storage disorder that is caused by the deficient activity of -galactosidase A and the resultant accumulation of globotriaosylceramide and related glycosphingolipids. The major debilitating manifestations of Fabry disease result from the progressive accumulation of globotriaosylceramide in the vascular endothelium, leading to ischemia and infarction, especially in the kidney, heart and brain. The disease is panethnic with

estimates of incidence range from 1 in 40,000 to 60,000 males. It predominantly affects males, although carrier (heterozygous) females also can be affected to a mild or severe degree because of random X-chromosomal inactivation.

Fabry patients can be divided into three categories of disease severity. In general, the severity of the disease is inversely correlated with enzyme activity.

- Hemizygotes (and some heterozygotes) with classical Fabry disease beginning in childhood, affecting many organ systems, and resulting in markedly decreased lifespan.
- Heterozygotes with mild to moderate disease or severe disease confined to a single organ system.
- Hemizygotes with residual enzyme activity who are diagnosed in the fourth, fifth, or sixth decade of life, when cardiac problems manifest ("cardiac variants").

Diagnosis of Fabry disease is confirmed by assay of galactosidase activity in leukocytes or plasma. In patients with the classic phenotype, levels of Gal A activity are very low or undetectable. Patients with detectable Gal A activity have a milder, variant phenotype. Female carriers can have normal to very low Gal A activity, therefore, their specific family mutation in the Gal A gene must be demonstrated. In addition, mutation or genetic linkage analysis may be necessary to establish carrier status. Most kindreds have family specific or private mutations; to date, more than 300 mutations have been identified.

The goal of enzyme replacement therapy is to prevent disease in young patients and both halt disease progression and reverse the underlying pathologic abnormalities and the resultant organ dysfunction in older patients. If plasma globotriaosylceramide levels prove to be a useful marker of disease burden and treatment efficacy, a goal of therapy may be to normalize plasma levels.

The safety and efficacy of Fabrazyme was established in a randomized, double-blind, placebo-controlled, multicenter clinical study in 82 adult patients with Fabry disease, all naïve to enzyme replacement therapy, evaluated time to first occurrence of a clinically significant event (renal, cardiac, or cerebrovascular event, or death). Patients received either Fabrazyme or placebo for up to 35 months (median follow up 18.5 months). A total of 14 of 51 (28%) of Fabrazyme-treated patients and 13 of 31 (42%) of placebo-treated patients experienced a clinically significant event. The estimated hazard ratio for the risk of clinically significant events was 0.57 (95% CI: 0.27, 1.22).

A long-term observational study assessed the rate of decline in renal function (eGFR) in 122 Fabrazyme treated patients (≥ 16 years) matched 1:1 with a cohort of 122 untreated patients matched based on age, sex, classic or non-classic Fabry disease subtype, and baseline estimated glomerular filtration rate (eGFR). The median follow-up time was 3 years in the untreated group and 4.5 years in the treated group, with a maximum of 5 years in both groups. The estimated mean slope of eGFR was -1.5 mL/min/1.73 m²/year in the Fabrazyme-treated group and -3.2 mL/min/1.73m²/year in the untreated group with a treatment difference of 1.7 mL/min/1.73m²/year (95% CI: 0.5, 3.0).

The most common adverse reactions which have occurred in $\geq 20\%$ of patients treated with Fabrazyme and $>2.5\%$ compared to placebo are upper respiratory tract infection, chills, fever, headache, cough, burning or prickling sensation in the hands, arms, legs or feet, fatigue, accumulation of fluids causing swelling in lower limbs, dizziness, and rash.

In March 2021, FDA granted approval to Agalsidase beta (Fabrazyme) for the treatment of adult patients and pediatric patients 2 years of age and older with confirmed Fabry disease. The safety and efficacy of Fabrazyme in pediatric patients was established in an open-label, single-arm, multicenter study in 16 pediatric patients with Fabry disease aged 8 to 16 years (median 12 years). At baseline, patients had median plasma β -GAL activity 0.2 nmol/hour/mL (range: 0.0, 2.0) and median leukocyte β -GAL activity 0.5 nmol/hour/mg (range: 0.0, 12.5). All 14 males had elevated plasma GL-3 levels (i.e., >7.03 μ g/mL) at baseline, whereas the two females had normal plasma GL-3 levels. Median eGFR was normal (112.1 mL/min/1.73 m²) at baseline and did not change during treatment, and median urinary protein was 151.0

mg/24 hr (range: 70.0, 431.0). All patients received Fabrazyme 1 mg/kg every two weeks for up to 48 weeks. Safety and efficacy was established based on similar results in the adult population.

The most common adverse reactions in pediatric patients (>20%) were headache, abdominal pain, pharyngitis, fever, nausea, vomiting, rhinitis, diarrhea, arthralgia, and dizziness.

Elfabrio's approval was based on a randomized, double-blind, active-controlled, clinical study spanning 24 months and including 77 patients with Fabry disease (BALANCE). Elfabrio was evaluated for noninferiority to agalsidase beta for the primary endpoint of median annualized change in estimated glomerular filtration rate (eGFR). The estimated mean slope of eGFR was $-2.514 \text{ mL/min/1.73 m}^2/\text{year}$ in the Elfabrio-treated group and $-2.155 \text{ mL/min/1.73 m}^2/\text{year}$ in the agalsidase beta group for a treatment difference of $-0.36 \text{ mL/min/1.73 m}^2/\text{year}$ (95% CI: -2.444 to 1.726) which met the prespecified noninferiority measures.

The overall rate of infusion-related reactions was 0.5 events per 100 infusions in the Elfabrio arm versus 3.9 events per 100 infusions in the agalsidase beta arm ($p < 0.0001$). Treatment-emergent antidrug antibody rates were numerically lower in the Elfabrio arm (12%) as compared to the agalsidase beta arm (20%). The most common adverse reactions occurring in $\geq 15\%$ of patients treated with Elfabrio were infusion-related reactions, nasopharyngitis, headache, diarrhea, fatigue, nausea, back pain, pain in extremity and sinusitis.

Pompe Disease

Pompe disease is an inherited disorder caused by the buildup of a complex sugar called glycogen in the body's cells. The accumulation of glycogen in certain organs and tissues, especially muscles, impairs their ability to function normally.

Researchers have described three types of Pompe disease, which differ in severity and the age at which they appear. These types are known as classic infantile-onset, non-classic infantile-onset, and late-onset.

1. The classic form of infantile-onset Pompe disease begins within a few months of birth. Infants with this disorder typically experience muscle weakness (myopathy), poor muscle tone (hypotonia), an enlarged liver (hepatomegaly), and heart defects. Affected infants may also fail to gain weight and grow at the expected rate (failure to thrive) and have breathing problems. If untreated, this form of Pompe disease leads to death from heart failure in the first year of life.
2. The non-classic form of infantile-onset Pompe disease usually appears by age one. It is characterized by delayed motor skills and progressive muscle weakness. The heart may be abnormally large (cardiomegaly), but affected individuals usually do not experience heart failure. The muscle weakness in this disorder leads to serious breathing problems, and most children with non-classic infantile-onset Pompe disease live only into early childhood.
3. The late-onset type of Pompe disease may not become apparent until later in childhood, adolescence, or adulthood. Late-onset Pompe disease is usually milder than the infantile-onset forms of this disorder and is less likely to involve the heart. Most individuals with late-onset Pompe disease experience progressive muscle weakness, especially in the legs and the trunk, including the muscles that control breathing. As the disorder progresses, breathing problems can lead to respiratory failure.

Lumizyme (alglucosidase alfa) provides an exogenous source of GAA, exerting enzymatic activity in cleaving glycogen. The U.S. Food and Drug Administration (FDA) has approved Lumizyme (alglucosidase alfa) for the treatment of patients with Pompe disease (GAA deficiency). Severe adverse reactions have occurred in patients receiving Lumizyme (alglucosidase alfa), including anaphylaxis, hypersensitivity reactions, immune-mediated reactions, and acute respiratory failure in patients with compromised cardiac and/or respiratory function. Due to these safety concerns, the FDA requires the prescribing information for Lumizyme (alglucosidase alfa) to include a black box warning.

Nexviazyme (avalglucosidase alfa-ngpt), an enzyme replacement therapy, to treat patients 1 year of age and older with late-onset Pompe disease. Nexviazyme is administered as an intravenous infusion. It is designed to improve the delivery of acid alpha-glucosidase (GAA), the enzyme lacking in patients with

Pompe disease, to help reduce glycogen accumulation. The approval was supported by positive data from the Phase 3 COMET trial, which compared treatment with Nexviazyme to treatment with Lumizyme (alglucosidase alfa). In the study, patients treated with Nexviazyme demonstrated a 2.4-point greater improvement in forced vital capacity (FVC) percent-predicted compared with patients treated with Lumizyme at Week 49, supporting the noninferiority of Nexviazyme. In addition, in a measurement of functional endurance with a 6-minute walk test, patients treated with Nexviazyme walked 30 meters farther than patients treated with Lumizyme at Week 49, a key secondary endpoint. Nexviazyme was studied head-to-head versus Lumizyme in the Phase 3 clinical trial COMET, in which Nexviazyme was found to be noninferior to Lumizyme in measures of forced vital capacity and the 6-minute walk test. Nexviazyme did not meet the threshold for superiority, although numerical improvements were observed. The safety profile, improvements in lower-extremity muscle strength, and quality of life were also similar between the two therapies. Administered as an intravenous (IV) infusion every other week, Nexviazyme is given at 20mg/kg for patients weighing 30kg (66 pounds) or less and 40mg/kg for those weighing more. Nexviazyme had previously received the FDA's Fast Track and Breakthrough Therapy designations for the treatment of patients with Pompe disease. The approval follows a priority review by the FDA.

Pombiliti (cipaglucosidase alfa-atga), a hydrolytic lysosomal glycogen-specific enzyme, in combination with Opfolda (miglustat), an enzyme stabilizer, is indicated for the treatment of adult patients with late-onset Pompe disease weighing ≥ 40 kg and who are not improving on their current ERT. While most patients with late-onset Pompe disease respond to the initial ERT for a few years, the treatment effect observed is highly variable among patients and often declines after 3 years. The efficacy of Pombiliti (cipaglucosidase alfa-atga) in combination with Opfolda (miglustat) was established in a phase III trial, of which most of the study population was treated with ≥ 2 years of ERT. Compared with a non-FDA-approved alglucosidase alfa product used in the trial, Pombiliti (cipaglucosidase alfa-atga) in combination with Opfolda (miglustat) significantly improved sitting forced vital capacity and significantly improved 6-minute walk distance in the ERT-experienced subpopulation. Similar to the other ERTs, Pombiliti (cipaglucosidase alfa-atga) has boxed warnings for severe hypersensitivity reactions and risk of acute cardiorespiratory failure. The combination of Pombiliti (cipaglucosidase alfa-atga) and Opfolda (miglustat) have additional warnings for infusion-associated reactions and are contraindicated in pregnancy due to embryo-fetal toxicity. While a consensus guideline recommended Lumizyme (alglucosidase alfa) in patients with symptomatic and suspected late-onset Pompe disease, the guidelines were written before the approval of the newer ERTs. Among the FDA-approved ERTs for late-onset Pompe disease, the combination of Pombiliti (cipaglucosidase alfa-atga) and Opfolda (miglustat) is studied mostly in ERT-experienced patients, and the study populations for Lumizyme (alglucosidase alfa) and Nexviazyme (avalglucosidase alfa-ngpt) were ERT-naïve; and thus, this new combination is only approved in patients who are not improving on current ERT. Lumizyme (alglucosidase alfa) is additionally indicated for infantile-onset Pompe disease. Overall, the combination of Pombiliti (cipaglucosidase alfa-atga) and Opfolda (miglustat) provides a third ERT treatment option for Pompe disease and is the first drug combination studied and approved for use in ERT-experienced patients with late-onset Pompe disease.

Mucopolysaccharidosis (MPS)

Mucopolysaccharidoses (MPS) is a group of rare, inherited storage disorders caused by the deficiency of specific lysosomal enzymes required for catabolism of glycosaminoglycans, which are long chains of carbohydrates. Glycosaminoglycans are used to help build bone, cartilage, tendons, corneas, skin, and connective tissues.

Mucopolysaccharidosis Type I (MPS I)

Mucopolysaccharidosis type I (MPS I) has a wide spectrum of clinical severity and has been subdivided into three phenotypes: Hurler Syndrome (severe), Hurler-Scheie syndrome (intermediate), and Scheie syndrome (mild). This disease is caused by a deficiency of α -L-iduronidase enzyme. Laronidase (Aldurazyme) is FDA approved for this condition.

Hurler's syndrome - most severe form, with neurologic, skeletal, and visceral involvement, including hepatosplenomegaly, cardiac disease, airway obstruction, mental retardation/development delay, corneal clouding, and severe skeletal abnormalities; death often occurs before the age of ten.

Hurler-Scheie syndrome - intermediate form characterized by slower progression of same types of complications, but with minimal-to-no mental retardation; death is usually later (e.g., 20s).

Scheie's syndrome - least severe with less extensive disease; some individuals may have a normal life span.

Mucopolysaccharidosis Type II (MPS II)

Mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, is an X-linked recessive disease caused by insufficient levels of lysosomal enzyme iduronate-2-sulfatase. There are 2 clinical subtypes of Hunter syndrome: MPS IIA and MPS IIB.

a condition that affects many different parts of the body and occurs almost exclusively in males. It is a progressively debilitating disorder; however, the rate of progression varies among affected individuals. Idursulfase (Elaprase) is FDA approved for this condition

At birth, individuals with MPS II do not display any features of the condition. Between ages two and four, they develop full lips, large, rounded cheeks, a broad nose, and an enlarged tongue (macroglossia). The vocal cords also enlarge, which results in a deep, hoarse voice. Narrowing of the airway causes frequent upper respiratory infections and short pauses in breathing during sleep. As the disorder progresses, individuals need medical assistance to keep their airway open.

Many other organs and tissues are affected in MPS II. Individuals with this disorder often have a large head (macrocephaly), a buildup of fluid in the brain (hydrocephalus), an enlarged liver and spleen (hepatosplenomegaly), and a soft out-pouching around the bellybutton (umbilical hernia) or lower abdomen (inguinal hernia). People with MPS II usually have thick skin that is not very stretchy. Some affected individuals also have distinctive white skin growths that look like pebbles. Most people with this disorder develop hearing loss and have recurrent ear infections. Some individuals with MPS II develop problems with the light-sensitive tissue in the back of the eye (retina) and have reduced vision. Carpal tunnel syndrome commonly occurs in children with this disorder and is characterized by numbness, tingling, and weakness in the hand and fingers. Narrowing of the spinal canal (spinal stenosis) in the neck can compress and damage the spinal cord. The heart is also significantly affected by MPS II, and many individuals develop heart valve problems. Heart valve abnormalities can cause the heart to become enlarged (ventricular hypertrophy) and can eventually lead to heart failure.

Mucopolysaccharidosis Type IVA (MPS IVA, B)

Mucopolysaccharidosis type IV (MPS IVA, B), is also known as Morquio syndrome. It is a progressive disease with predominant skeletal manifestations, like skeletal abnormalities, loose joints, and underdevelopment of odontoid process. MPS IV has two subtypes: MPS IVA is due to N-acetylgalactosamine-6-sulfatase deficiency, and MPS IVB is due to beta-galactosidase deficiency. Of MPS IV subtypes, only MPS IVA can be treated with exogenous enzymes. The FDA approved elosulfase alfa (Vimizim™), for patients with MPS IVA or Morquio syndrome.

Mucopolysaccharidosis Type VI (MPS VI)

Mucopolysaccharidosis type VI (MPS VI), also known as Maroteaux-Lamy syndrome, is characterized by the absence or marked reduction in N-acetylgalactosamine 4-sulfatase. Galsulfase (Naglazyme®) is FDA approved for this condition.

Mucopolysaccharidosis type VII (MPS VII)

Mucopolysaccharidosis type VII (MPS VII), also known as Sly syndrome, is a deficiency in enzyme beta-glucuronidase. Vestronidase alfa-vjkb (Mepsevii™) is approved by the FDA for the treatment for this condition.

Infantile Neuronal Ceroid Lipofuscinosis Type 2 (CLN2)

On April 27, 2017, the FDA approved Brineura (cerliponase alfa), an enzyme replacement therapy, indicated to slow the loss of ambulation in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase (TPP1) deficiency. In July 2024, the FDA approved an expanded indication for Brineura (cerliponase alfa) to slow the loss of ambulation in children of all ages with CLN2, also known as TPP1.

CLN2 disease is one of a group of disorders known as neuronal ceroid lipofuscinoses (NCLs), collectively referred to as Batten disease. CLN2 disease is a rare inherited disorder that primarily affects the nervous system. In the late infantile form of the disease, signs and symptoms typically begin between ages 2 and 4. The initial symptoms usually include language delay, recurrent seizures (epilepsy) and difficulty coordinating movements (ataxia). Affected children also develop muscle twitches (myoclonus) and vision loss. CLN2 disease affects essential motor skills, such as sitting and walking. Individuals with this condition often require the use of a wheelchair by late childhood and typically do not survive past their teens. Batten disease is relatively rare, occurring in an estimated two to four of every 100,000 live births in the United States. Brineura is the first drug FDA approved to treat CLN2. Continuing studies will test its use for children under two years of age and its long-term effects over 10 years.

The FDA approval of Brineura was based on a non-randomized single-arm dose escalation clinical study with extension in symptomatic pediatric patients with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease, confirmed by TPP1 deficiency. Brineura-treated patients were compared to untreated patients from a natural history cohort. The Motor domain of a CLN2 Clinical Rating Scale was used to assess disease progression. Scores ranged from 3 (grossly normal) to 0 (profoundly impaired) with unit decrements representing milestone events in the loss of motor function (ability to walk or crawl). Twenty-four patients, aged 3 to 8 years were enrolled in the Brineura single-arm clinical study. One patient withdrew after week 1 due to inability to continue with study procedures; 23 patients were treated with Brineura 300 mg every other week for 48 weeks, and continued treatment during the extension period.

In the clinical study with extension, patients were assessed for decline in the Motor domain of the CLN2 Clinical Rating Scale at 48, 72 and 96 weeks. Decline was defined as having an unreversed (sustained) 2-category decline or an unreversed score of 0 in the Motor domain of the CLN2 Clinical Rating Scale. Patients' responses to Brineura treatment were evaluated if at screening a combined Motor plus Language CLN2 score of less than 6 was recorded. Two patients with a combined Motor plus Language CLN2 score of 6 were excluded from the analyses; they maintained that score throughout the study period. Motor scores of the 22 Brineura-treated patients in the clinical study with extension were compared to scores of the independent natural history cohort that included 42 untreated patients who satisfied inclusion criteria for the clinical study. The results of logistic modeling with covariates (screening age, screening motor score, genotype: 0 key mutations (yes/no)), demonstrated the odds of Brineura-treated patients not having a decline by 96 weeks were 13 times the odds of natural history cohort patients not having a decline [Odds Ratio (95% CI): 13.1 (1.2, 146.9)].

In an unadjusted non-randomized comparison, of the 22 patients treated with Brineura and evaluated for efficacy at week 96, 21 (95%) did not decline, and only the patient who terminated early was deemed to have a decline in the Motor domain of the CLN2 Clinical Rating Scale. Results from the natural history cohort demonstrated progressive decline in motor function; of the 42 patients in the natural history cohort 21 (50%) experienced an unreversed (sustained) 2-category decline or unreversed score of 0 in the Motor domain of the CLN2 Clinical Rating Scale over 96 weeks. To further assess efficacy, the 22 patients from the Brineura clinical study with a baseline combined Motor plus Language CLN2 score less than 6 were matched to 42 patients in the natural history cohort. Patients were matched based on the following covariates: baseline age at time of screening within 3 months, genotype (0, 1, or 2 key mutations), and baseline Motor domain CLN2 score at time of screening. Using the Motor domain of the CLN2 Clinical Rating Scale, decline was defined as having an unreversed 2-category decline or an unreversed score of 0. At 96 weeks, the matched analysis based on 17 pairs demonstrated fewer declines in the Motor domain for Brineura-treated patients compared to untreated patients in the natural history cohort.

Lysosomal Acid Lipase Deficiency (LALD)

Lysosomal acid lipase deficiency (LALD) is a rare, chronic, progressive, inherited disorder. It affects the body's ability to produce an enzyme called lysosomal acid lipase (LAL). This enzyme is needed for the breakdown of fats (lipids) and cholesterol in the body. In affected individuals when the LAL enzyme is missing or deficient, fats (lipids) accumulate in organs and tissues throughout the body, primarily leading to liver disease (fibrosis, cirrhosis, and eventually liver failure). There are two forms of the condition. The most severe and rarest form begins in infancy. The less severe form can begin from childhood to late adulthood.

In December 2015, the U.S. Food and Drug Administration (FDA) approved Kanuma (sebelipase alfa), the first therapy that treats the underlying cause of the disease. Previously, there were only supportive therapies available for LALD.

Molybdenum Cofactor Deficiency Type A

Molybdenum cofactor deficiency (MoCD) is a rare inherited metabolic disorder characterized by neonatal onset intractable seizures, dysmorphic facies, dislocated ocular lenses, and severe psychomotor retardation. Infants with this condition appear normal at birth, but within a week have difficulty feeding and develop seizures that do not improve with treatment. Brain abnormalities, including atrophy of brain tissue, lead to severe developmental delay and affected individuals usually exhibit loss of individual function. Molybdenum cofactor deficiency is a rare condition that is estimated to occur in 1 in 100,000 to 200,000 newborns worldwide. The disease is caused by mutations in the MOCS1, MOCS2, or GPHN gene, and there are three forms of the disorder, named types A, B, and C (or complementation groups A, B, and C). MOCS1 gene mutations cause type A, MOCS2 gene mutations cause type B, and GPHN gene mutations cause type C, although the signs and symptoms of each form overlap. The proteins produced from each of these genes are involved in the biosynthesis of molybdenum cofactor, which is essential to the function of several enzymes. These enzymes help break down (metabolize) different substances in the body, some of which are toxic if not metabolized. Mutations in the MOCS1, MOCS2, or GPHN gene reduce or eliminate the function of the associated protein, which impairs molybdenum cofactor biosynthesis and metabolic enzyme function. The resulting loss of enzyme activity leads to buildup of sulfite, S-sulfocysteine, xanthine, hypoxanthine, and low levels of uric acid in the blood. Sulfite build-up is toxic to the brain, and researchers suggest that damage caused by the abnormally high levels of sulfite leads to encephalopathy, seizures, and the other features of molybdenum cofactor deficiency. Nulibry is a cyclic pyranopterin monophosphate (cPMP) agent FDA approved to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A, although affected individuals usually do not survive past early childhood.

On February 28, 2021, the FDA approved Nulibry (fosdenopterin) a cyclic pyranopterin monophosphate (cPMP) indicated to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A.

The safety and efficacy of Nulibry was based on results from 2 prospective open-label single-arm dose escalation studies and 1 retrospective observational study in patients with a confirmed diagnosis of MoCD Type A. Efficacy of Nulibry and rcPMP were assessed in a combined analysis of 13 patients with genetically confirmed MoCD Type A from Study 1 (n=8), Study 2 (n=1), and Study 3 (n=4) who received substrate replacement therapy with Nulibry or rcPMP. Patients treated with Nulibry were titrated from their initial dose to a maximum of 0.9 mg/kg administered once daily as an intravenous infusion. Efficacy was assessed by comparing overall survival in pediatric patients treated with Nulibry or rcPMP (n=13) with an untreated natural history cohort of pediatric patients with genetically confirmed MoCD Type A who were genotype-matched to the treated patients (n=18). Patients treated with Nulibry or rcPMP had an improvement in overall survival compared to the untreated, genotype-matched, historical control group. Kaplan Meier estimates for overall survival in patients treated with Nulibry or rcPMP vs. control group showed that 92% of treated patients had a 1-year survival probability vs. 67% in the control group, and 84% of treated patients had a 3-year survival probability vs. 55% in the control group. For patients treated with Nulibry or rcPMP, there were 2 deaths (15%) total vs. 12 deaths (67%) seen in the control group. Treatment with Nulibry

resulted in a reduction in urine concentrations of SSC in patients with MoCD Type A and the reduction was sustained with long-term treatment over 48 months. Following treatment with Nulibry in Studies 1 and 2 (n=9), the mean \pm SD levels of urinary SSC normalized to creatinine ranged from 11 (\pm 8.5) to 7 (\pm 2.4) μ mol/mmol from Month 3 to Month 48.

The most common adverse reactions (>25%) were catheter-related complications, pyrexia, viral infection, pneumonia, otitis media, vomiting, cough/sneezing, viral upper respiratory infection, gastroenteritis, bacteremia, and diarrhea. Caregivers should be advised to avoid patient exposure to sunlight due to photosensitivity risk.

Acid Sphingomyelinase Deficiency (ASMD)

Acid sphingomyelinase deficiency (ASMD), also known as Niemann-Pick disease, is a rare progressive genetic disorder in which there is a mutation of sphingomyelin phosphodiesterase 1 (SMPD1) gene resulting in a deficiency in the enzyme acid sphingomyelinase (ASM). ASM metabolizes sphingomyelin, and a deficiency of ASM will result in accumulation of sphingomyelin in various tissues causing hepatomegaly, splenomegaly, respiratory complications when accumulating in the lungs, and potentially other symptoms depending on the individual patient. Initial diagnosis and classification can be difficult and is made based on factors including age of onset and the severity of symptoms. Type A ASMD is an aggressive form generally seen in infants causing neurologic deterioration, severe hepatosplenomegaly, jaundice, ascites, and other gastrointestinal or respiratory symptoms leading to failure to thrive and is often fatal by 3 years of age. Types A/B and B ASMD may be seen in a range of ages from infancy to adulthood, lead to more mild symptoms, and rarely involve neurological disorders. Types A/B and B have variety of symptoms based on the tissue sphingomyelin is accumulating in and may include: hepatosplenomegaly causing low platelet levels, scarring of the liver, or dyslipidemia; gradual deterioration of lung function causing dyspnea or recurrent respiratory infections; children may experience delays in growth and development; osteopenia and bone pain; in rare cases of central nervous system involvement, nystagmus, ataxia, peripheral neuropathy, abnormalities of the retina, and psychiatric disorders have been reported. It is estimated that 1 in 250,000 individuals in the US have ASMD, but that number may be underestimated due to the difficulty in properly diagnosis this disorder.

On August 31, 2022 the FDA approved Xenpozyme (olipudase alfa-rpcp) as the first medication indicated for adult and pediatric patients with acid sphingomyelinase deficiency (ASMD). Xenpozyme (olipudase alfa-rpcp) for intravenous infusion is an exogenous source of ASM for the treatment of non-central nervous system manifestations of ASMD.

Xenpozyme (olipudase alfa-rpcp) showed superiority to placebo in a phase II/III international, double-blind, placebo-controlled trial of adults (ASCEND; N=36) in improving lung function (22% vs 3%), decreasing liver (-28% vs -1.5%) and spleen (-39% vs 0.5%) volumes, and increasing platelet count (17% vs 2.5%) compared to baselines at week 52 of the trial. For pediatric patients, Xenpozyme (olipudase alfa-rpcp) demonstrated efficacy in a phase I/II, multicenter, open-label, single arm trial of pediatric patients (ASCEND-Peds; N=20) by improving lung function (diffusing capacity of the lung for carbon monoxide increase by 33%; p=0.0053), improving least square mean percent change from baseline for splenomegaly and hepatomegaly (>40%; p<0.0001), increased platelet count (34%; p=0.0003), and height Z-scores (0.56; p<0.0001) at week 52.

Xenpozyme (olipudase alfa-rpcp) carries a black box warning regarding severe hypersensitivity reactions including anaphylaxis that requires immediate availability of medical support measures, including cardiopulmonary resuscitation equipment, during Xenpozyme administration. Additionally, if a patient experiences a severe hypersensitivity reaction, a desensitization procedure to Xenpozyme should be considered. Elevated transaminases have been noted and baseline alanine aminotransferase (ALT)/aspartate aminotransferase (AST) is recommended one month prior to initiation and periodically during therapy. Other common adverse events included headache, cough, diarrhea, hypotension, ocular hyperemia, pyrexia, rhinitis, and abdominal pain.

Alpha-Mannosidosis

Alpha-mannosidosis is a rare genetic lysosomal storage disorder characterized by a deficiency of the enzyme alpha-D-mannosidase due to a gene mutation in the *MAN2B1* gene leading to gradual accumulation of oligosaccharides in the cells of various organs. The clinical manifestations of alpha-mannosidosis include coarse facial features, mild-to-moderate intellectual disability, impaired hearing, clinical or radiographic skeletal abnormalities, immunodeficiency, and primary central nervous system disease – mainly cerebellar involvement causing ataxia. There are three forms of alpha-mannosidosis: a mild form recognized after age ten years with absence of skeletal abnormalities, myopathy, and slow progression (Type 1), a moderate form recognized before age ten years with presence of skeletal abnormalities, myopathy, and slow progression (Type 2) and a severe form manifested as prenatal loss or early death from progressive central nervous system involvement or infection (type 3). The disease affects approximately 1 in every 500,000 individuals worldwide.

Lamzede (velmanase alfa-tycv) was approved by the FDA on February 16, 2023 as the first enzyme replacement therapy approved in the U.S. for the treatment of the non-central nervous system manifestations of alpha-mannosidosis. The efficacy of Lamzede (velmanase alfa-tycv) was evaluated in a 52-week, phase 3, multicenter, randomized, double-blind, placebo-controlled study named rhLAMAN-05. It enrolled 25 adult and pediatric patients. Lamzede (velmanase alfa-tycv) showed a significant reduction of serum oligosaccharides in patients treated with Lamzede (velmanase alfa-tycy) compared to placebo. The clinical endpoints assessed at 12 months (3-minute stair climbing test [3MSCT], 6-minute walking test [6MWT] and forced vital capacity [FVC]) all favored the Lamzede (velmanase alfa-tycv) group.

Lamzede (velmanase alfa-tycy) carries a black box warning regarding severe hypersensitivity reactions including anaphylaxis that requires immediate availability of medical support measures, including cardiopulmonary resuscitation equipment, during Lamzede administration. Additionally, if a patient experiences a severe hypersensitivity reaction, a desensitization procedure to Lamzede should be considered. Other adverse reactions included nasopharyngitis, pyrexia, headache, and arthralgia.

PROCEDURES AND BILLING CODES

To report provider services, use appropriate CPT* codes, Alpha Numeric (HCPCS level 2) codes, Revenue codes, and/or ICD diagnostic codes.

- J1931 - Injection, laronidase, (Aldurazyme), 0.1 mg
- J0567 - Injection, cerliponase alfa, (Brineura), 1 mg
- J1743 - Injection, idursulfase, (Elaprase), 1 mg
- J0180 - Injection, agalsidase beta, (Fabrazyme), 1 mg
- J2840 - Injection, sebelipase alfa, (Kanuma), 1 mg
- J0221 - Injection, alglucosidase alfa, (Lumizyme), 10 mg
- J3397 - Injection, vestronidase alfa-vjvk, (Mepsevii), 1 mg
- J1458 - Injection, galsulfase, (Naglazyme), 1 mg
- J1322 - Injection, elosulfase alfa, (Vimizim), 1 mg
- J0220 - Injection, alglucosidase alfa, 10 mg, not otherwise specified
- C9399 - Unclassified drugs or biologicals
- C9085 - Injection, avalglucosidase alfa-ngpt, (Nexviazyme), 4 mg – cancelled 4/1/2022
- C9167 – Injection, apadamtase alfa, 10 units (cancelled 7/1/2024)
- J0219 – Injection, avalglucosidase alfa-ngpt, (Nexviazyme), 4 mg – effective 4/1/2022
- J0218 – Injection, olipudase alfa-rpcp, (Xenpozyme), 1mg – effective 4/1/2023
- J0217 – Injection, velmanase alfa-tycv, 1 mg (effective 1/1/2024)
- J1202 – Miglustat, oral, 65 mg (effective 4/1/2024)
- J1203 – Injection, cipaglucosidase alfa-atga, 5 mg (effective 4/1/2024)
- J1809 – Injection, fosdenopterin, 0.1 mg (effective 10/1/2025)

- J2508 – Injection, pegunigalsidase alfa-iwxj, 1 mg (effective 1/1/2024)
- J7171 – Injection, adamts13, recombinant-krhn, 10 iu (effective 7/1/2024)
- J3490 - Unclassified drugs
- J3590 - Unclassified biologics
- G0138 – Intravenous infusion of cipaglucoisidase alfa-atga, including provider/supplier acquisition and clinical supervision of oral administration of miglustat in preparation of receipt of cipaglucoisidase alfa-atga (effective 4/1/2024)

REFERENCES

- Adzynma [package insert]. Lexington, MA: Takeda Pharmaceuticals U.S.A., Inc.; June 2024.
- Aldurazyme [package insert]. Cambridge, MA: Genzyme Corporation; December 2023.
- Wraith JE, Clarke LA, Beck M, et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). *J Pediatr.* 2004;144:581-588.
- Muenzer, Wraith JE, Clarke LA; International Consensus Panel on Management and Treatment of Mucopolysaccharidosis I. Mucopolysaccharidosis I: management and treatment guidelines. *Pediatrics.* 2009 Jan;123(1):19-29.
- Brineura [package insert]. Novato, CA: BioMarin Pharmaceutical, Inc. July 2024.
- Fietz M, AlSayed M, Burke, D, et al. Diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease): Expert recommendations for early detection and laboratory diagnosis. *Molecular Genetics and Metabolism.* 2016 (11): 160-167.
- Elaprase [package insert]. Lexington, MA: Shire Human Genetic Therapies, Inc.; September 2021.
- Fabrazyme [package insert]. Cambridge, MA: Genzyme Corporation; July 2024.
- Desnick RJ, Brady RO. Fabry disease in childhood. *J Pediatr.* 2004;144(5 Suppl): S20-S26.
- Biegstraaten M, Arngrimsson R, Barbey F, et al. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. *Orphanet J Rare Dis.* 2015; 1036.
- Ortiz A, Germain DP, Desnick RJ, et al. Fabry disease revisited: Management and treatment recommendations for adult patients. *Mol Genet Metab.* 2018;123(4):416-427.
- Desnick RJ, Brady R, Barranger J, et al. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, and enzyme replacement therapy. *Ann Intern Med.* 2003; 138(4):338.
- Muenzer J, Beck M, Eng CM, et al. Multidisciplinary management of Hunter syndrome. *Pediatrics.* 2009;124(6): e1228-e1239.
- Kanuma [package insert]. Boston, MA: Alexion Pharmaceuticals Inc.; July 2024.
- Burton BK, Balwani, M, Feillet F, et al. A Phase 3 Trial of Sebelipase Alfa in Lysosomal Acid Lipase Deficiency. *N Engl J Med.* 2015; 373: 1010-20.
- Lumizyme [package insert]. Cambridge, MA: Genzyme Corporation; December 2024.
- Mepsevii [package insert]. Novato, CA: Ultragenyx; December 2020.
- ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT01856218. An Open Label Phase 1/2 Study to Assess the Safety, Efficacy and Dose of Study Drug UX003 Recombinant Human Beta- glucuronidase (rhGUS) Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7); January 31, 2018. Available at: <https://clinicaltrials.gov/ct2/show/NCT01856218?term=NCT01856218&rank=1>.
- ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT02230566. A Phase 3 Study of UX003 Recombinant Human Betaglucoisidase (rhGUS) Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7); Feb 16, 2018. Available at: <https://clinicaltrials.gov/ct2/show/NCT02230566?term=NCT02230566&rank=1>.
- ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT02432144. A Long Term Open-Label Treatment and Extension Study of UX003 rhGUS Enzyme

Replacement Therapy in Subjects With MPS 7; November 6, 2017. Available at: <https://clinicaltrials.gov/ct2/show/NCT02432144?term=NCT02432144&rank=1>.

- Harmatz P, et al. A novel Blind Start study design to investigate vestronidase alfa for mucopolysaccharidosis VII, an ultra-rare genetic disease. *Mol Genet Metab*. 2018 Apr;123(4):488-494.
- Naglazyme [package insert]. Novato, CA: BioMarin Pharmaceutical Inc.; September 2024.
- Nulibry [package insert]. Boston, MA: Origin Biosciences, Inc.; October 2022.
- Atwal PS, Scaglia F. Molybdenum cofactor deficiency. *Mol Genet Metab*. 2016;117(1):1-4.
- Schwahn BC, Van Spronsen FJ, Belaidi AA, et al. Efficacy and safety of cyclic pyranopterin monophosphate substitution in severe molybdenum cofactor deficiency type A: a prospective cohort study. *Lancet*. 2015; 386: 1955-1963.
- ClinicalTrials.gov. Study of ORGN001 (formerly ALXN1101) in neonates with molybdenum cofactor deficiency (MOCD) type A. Available at: <https://clinicaltrials.gov/ct2/show/NCT02629393>. Accessed: November 2, 2021.
- ClinicalTrials.gov. Safety & efficacy study of ORGN001 (formerly ALXN1101) in pediatric patients with MoCD type A currently treated with rcPMP. Available at: <https://clinicaltrials.gov/ct2/show/NCT02047461>. Accessed: November 2, 2021.
- Revcovi [package insert]. Gaithersburg, MD: Leadiant Biosciences, Inc.; August 2022.
- Akyol, M.U., Alden, T.D., Amartino, H. et al. Recommendations for the management of MPS VI: systematic evidence- and consensus-based guidance. *Orphanet J Rare Dis* 14, 118 (2019).
- Vimizim [package insert]. Novato, CA: BioMarin Pharmaceutical Inc.; December 2019.
- Hendriksz CJ, Berger KI, Giugliani R, et al. International guidelines for the management and treatment of Morquio A syndrome. *Am J Med Genet A*. 2015;167A(1):11-25.
- Nexviazyme [package insert]. Cambridge, MA: Genzyme Corporation; September 2023.
- Xenpozyme [package insert]. Cambridge, MA: Genzyme Corporation; December 2023.
- ClinicalTrials.gov [Internet]. Identifier NCT02004691. Efficacy, Safety, Pharmacodynamic, and Pharmacokinetics Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency; May 24, 2022. Available at: <https://clinicaltrials.gov/ct2/show/NCT02004691>.
- Wasserstein M, Lachmann R, Hollak C, et al. A randomized, placebo-controlled clinical trial evaluating olipudase alfa enzyme replacement therapy for chronic acid sphingomyelinase deficiency (ASMD) in adults: One-year results. *Genet Med*. 2022;24(7):1425-1436.
- McGovern MM, Dionisi-Vici C, Giugliani R, et al. Consensus recommendation for a diagnostic guideline for acid sphingomyelinase deficiency. *Genet Med*. 2017;19(9):967-974.
- Lamzede [package insert]. Cary, NC: Chiesi USA, Inc; February 2023.
- Malm D, Nilssen Ø. Alpha-Mannosidosis. 2001 Oct 11 [updated 2019 Jul 18]. In: Adam MP, Everman DB, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. *GeneReviews*® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2023. PMID: 20301570. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK1396/> Accessed on: March 16, 2023.
- Elfabrio [package insert]. Cary, NC: Chiesi USA, Inc.; May 2024.
- Asmis LM, Serra A, Krafft A, et al. Recombinant ADAMTS13 for Hereditary Thrombotic Thrombocytopenic Purpura. *N Engl J Med* 2022; 387: 2356-2361.
- Pombiliti [package insert]. Philadelphia, PA: Amicus Therapeutics US, LLC; July 2024.
- Opfolda [package insert]. Philadelphia, PA: Amicus Therapeutics US, LLC; July 2024.

POLICY HISTORY

Policy #: 05.02.91

Policy Creation: February 2022

Reviewed: January 2026

Revised: January 2026

Current Effective Date: March 19, 2026